Quadrivalent influenza vaccine
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Vaccine containing influenza virus haemagglutinin (HA) proteins.
Influenza - prophylaxis
Administer 0.5ml dose.
For intramuscular injection only.
Children under 18 years
Precautions and Warnings
Predisposition to bleeding complications
Severe febrile conditions
Postpone immunisation if there is active or suspected infection
Impaired response possible in immunocompromised patients
Vaccine may not be effective in 100% of patients
Do not mix with other vaccines in the same syringe
Do not use if any signs of precipitate or particulate matter apparent
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Management of cases of shock should follow current medical standards
Follow national immunisation guidelines
Syncope can occur prior to, or following any vaccination as a psychogenic response to the needle injection. Neurological symptoms such as visual disturbances, paraesthesia and tonic-clonic limb movements during recover. To manage syncope, procedures should be in place to prevent falling and injury.
Pregnancy and Lactation
Use quadrivalent influenza vaccine with caution during pregnancy.
The manufacturer advises an assessment of the risks and benefits by a health care professional should be performed before using quadrivalent influenza vaccine during pregnancy. At the time of writing there is limited published information regarding the use of quadrivalent influenza vaccine during pregnancy. Potential risks are unknown.
Use quadrivalent influenza vaccine with caution during breastfeeding.
The manufacturer advises an assessment of the risks and benefits by a health care professional should be performed before using quadrivalent influenza vaccine during breastfeeding. The presence of quadrivalent influenza vaccine in human breast milk and its effect on exposed infants are unknown.
Local pain (injection site)
Local reaction at injection site
Slight redness of the skin
Swelling (injection site)
Tenderness (injection site)
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: May 2021
Summary of Product Characteristics: Supemtek solution for injection in pre-filled syringe Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture). Sanofi Pasteur. Revised January 2021.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.